- Home
- / News & Media Center
- / Blood-based biomarkers may predict mild behavioral impairment in older Asian adults
Blood-based biomarkers may predict mild behavioral impairment in older Asian adults
Posted on
Source: Healio
Healio | March 13, 2025
Analysis of blood-based biomarkers may be a reliable method to predict behavioral issues in older populations of Asian descent with varied neuropathology, researchers reported in the Journal of Clinical Psychiatry.
Liao and fellow researchers sought to examine the mechanisms behind mild behavioral impairment (MBI) and whether a series of Alzheimer’s disease-related blood-based biomarkers could predict its incidence in a small cohort of older adults of Asian descent..
Share This Post
Related Posts
Industry Insights: Multi-omic Diagnostics
Multi-omic diagnostics are reshaping how researchers and clinicians approach complex diseases, offering deeper biological insights through the integration of multiple data types. In this interview with The Pathologist, industry experts…
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…